Advertisement

Translational Approaches to Medication Development

  • Selena BartlettEmail author
  • Markus Heilig
Chapter
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 13)

Abstract

Alcohol accounts for major disability worldwide and available treatments are insufficient. A massive growth in the area of addiction neuroscience over the last several decades has not resulted in a corresponding expansion of treatment options available to patients. In this chapter, we describe our experience with building translational research programs aimed at developing novel pharmacotherapies for alcoholism. The narrative is based on experience and considerations made in the course of building these programs, and work on four mechanisms targeted by our libraries: cholinergic nicotine receptors, receptors for corticotropin-releasing hormone (CRH), neurokinin 1 (NK1) receptors for substance P (SP) and hypocretin/orexin receptors. Around this experience, we discuss issues we believe to be critical for successful translation of basic addiction neuroscience into treatments, and complementarities between academic and other actors that in our assessment need to be harnessed in order to bring treatments to the clinic.

Keywords

Nicotinic Varenicline Corticotropin-releasing hormone Substance P Neurokinin Orexin Hypocretin 

References

  1. Ahlenius S, Carlsson A, Engel J, Svensson T, Sodersten P (1973) Antagonism by alpha methyltyrosine of the ethanol-induced stimulation and euphoria in man. Clin Pharmacol Ther 14:586–591PubMedGoogle Scholar
  2. Ahmed SH, Koob GF (1998) Transition from moderate to excessive drug intake: change in hedonic set point. Science 282:298–300PubMedGoogle Scholar
  3. Albuquerque EX, Pereira EF, Alkondon M, Rogers SW (2009) Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev 89:73–120PubMedCentralPubMedGoogle Scholar
  4. Alheid GF, Beltramino CA, De Olmos JS, Forbes MS, Swanson DJ, Heimer L (1998) The neuronal organization of the supracapsular part of the stria terminalis in the rat: the dorsal component of the extended amygdala. Neuroscience 84:967–996PubMedGoogle Scholar
  5. Altshuler HL, Phillips PE, Feinhandler DA (1980) Alteration of ethanol self-administration by naltrexone. Life Sci 26:679–688PubMedGoogle Scholar
  6. Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM et al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence–the COMBINE study: a randomized controlled trial. JAMA-J Am Med Assoc 295:2003–2017Google Scholar
  7. Anton RF, Oroszi G, O’Malley S, Couper D, Swift R, Pettinati H et al (2008) An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE) study. Arch Gen Psychiatry 65:135–144PubMedCentralPubMedGoogle Scholar
  8. Baldwin HA, Rassnick S, Rivier J, Koob GF, Britton TK (1991) CRF antagonist reverses the “anxiogenic” response to ethanol withdrawal in the rat. Psychopharmacology (Berl) 103:227–232Google Scholar
  9. Ballard TM, Sanger S, Higgins GA (2001) Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 412:255–264PubMedGoogle Scholar
  10. Barazangi N, Role LW (2001) Nicotine-induced enhancement of glutamatergic and GABAergic synaptic transmission in the mouse amygdala. J Neurophysiol 86:463–474PubMedGoogle Scholar
  11. Barr CS, Goldman D (2006) Non-human primate models of inheritance vulnerability to alcohol use disorders. Addict Biol 11:374–385PubMedGoogle Scholar
  12. Barr CS, Schwandt M, Lindell SG, Chen SA, Goldman D, Suomi SJ et al (2007) Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry 64:369–376PubMedGoogle Scholar
  13. Barr CS, Dvoskin RL, Gupte M, Sommer W, Sun H, Schwandt ML et al (2009) Functional CRH variation increases stress-induced alcohol consumption in primates. Proc Natl Acad Sci USA 106:14593–14598PubMedGoogle Scholar
  14. Benwell ME, Balfour DJ (1979) Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology (Berl) 63:7–11Google Scholar
  15. Bierut LJ, Stitzel JA, Wang JC, Hinrichs AL, Grucza RA, Xuei X et al (2008) Variants in nicotinic receptors and risk for nicotine dependence. Am J psychiatry 165:1163–1171PubMedCentralPubMedGoogle Scholar
  16. Binneman B, Feltner D, Kolluri S, Shi Y, Qiu R, Stiger T (2008) A 6-week randomized, placebo-controlled trial of CP-316, 311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry 165:617–620PubMedGoogle Scholar
  17. Bisetti A, Cvetkovic V, Serafin M, Bayer L, Machard D, Jones BE et al (2006) Excitatory action of hypocretin/orexin on neurons of the central medial amygdala. Neuroscience 142:999–1004PubMedGoogle Scholar
  18. Blomqvist O, Engel JA, Nissbrandt H, Soderpalm B (1993) The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine. Eur J Pharmacol 249:207–213PubMedGoogle Scholar
  19. Blomqvist O, Ericson M, Johnson DH, Engel JA, Soderpalm B (1996) Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment. Eur J Pharmacol 314:257–267PubMedGoogle Scholar
  20. Blomqvist O, Ericson M, Engel JA, Soderpalm B (1997) Accumbal dopamine overflow after ethanol: localization of the antagonizing effect of mecamylamine. Eur J Pharmacol 334:149–156PubMedGoogle Scholar
  21. Blomqvist O, Hernandez-Avila CA, Van Kirk J, Rose JE, Kranzler HR (2002) Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol. Alcohol Clin Exp Res 26:326–331PubMedGoogle Scholar
  22. Boileau I, Assaad JM, Pihl RO, Benkelfat C, Leyton M, Diksic M et al (2003) Alcohol promotes dopamine release in the human nucleus accumbens. Synapse 49:226–231PubMedGoogle Scholar
  23. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L et al (1998) Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95:9608–9613PubMedGoogle Scholar
  24. Booker TK, Collins AC (1997) Long-term ethanol treatment elicits changes in nicotinic receptor binding in only a few brain regions. Alcohol (Fayetteville, N Y) 14:131–140 Google Scholar
  25. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 49:589–601PubMedGoogle Scholar
  26. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF et al (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 102:19168–19173PubMedGoogle Scholar
  27. Bouza C, Angeles M, Munoz A, Amate JM (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99:811–828PubMedGoogle Scholar
  28. Breese GR, Overstreet DH, Knapp DJ (2005a) Conceptual framework for the etiology of alcoholism: a “kindling”/stress hypothesis. Psychopharmacology (Berl) 178:367–380Google Scholar
  29. Breese GR, Overstreet DH, Knapp DJ, Navarro M (2005b) Prior multiple ethanol withdrawals enhance stress-induced anxiety-like behavior: inhibition by CRF1–and benzodiazepine-receptor antagonists and a 5-HT1a-receptor agonist. Neuropsychopharmacology 30:1662–1669PubMedCentralPubMedGoogle Scholar
  30. Brodie MS (2002) Increased ethanol excitation of dopaminergic neurons of the ventral tegmental area after chronic ethanol treatment. Alcohol Clin Exp Res 26:1024–1030PubMedGoogle Scholar
  31. Brodie MS, Shefner SA, Dunwiddie TV (1990) Ethanol increases the firing rate of dopamine neurons of the rat ventral tegmental area invitro. Brain Res 508:65–69PubMedGoogle Scholar
  32. Brodie MS, Pesold C, Appel SB (1999) Ethanol directly excites dopaminergic ventral tegmental area reward neurons. Alcohol Clin Exp Res 23:1848–1852PubMedGoogle Scholar
  33. Brody AL, Mandelkern MA, London ED, Childress AR, Lee GS, Bota RG et al (2002) Brain metabolic changes during cigarette craving. Arch Gen Psychiatry 59:1162–1172PubMedGoogle Scholar
  34. Brownell KD, Marlatt GA, Lichtenstein E, Wilson GT (1986) Understanding and preventing relapse. Am Psychol 41:765–782PubMedGoogle Scholar
  35. Budygin EA, Phillips PE, Wightman RM, Jones SR (2001) Terminal effects of ethanol on dopamine dynamics in rat nucleus accumbens: an in vitro voltammetric study. Synapse (New York, N Y) 42:77–79Google Scholar
  36. Bunney EB, Appel SB, Brodie MS (2001) Electrophysiological effects of cocaethylene, cocaine, and ethanol on dopaminergic neurons of the ventral tegmental area. J Pharmacol Exp Ther 297:696–703PubMedGoogle Scholar
  37. Butt CM, King NM, Stitzel JA, Collins AC (2004) Interaction of the nicotinic cholinergic system with ethanol withdrawal. J Pharmacol Exp Ther 308:591–599PubMedGoogle Scholar
  38. Butt CM, King NM, Hutton SR, Collins AC, Stitzel JA (2005) Modulation of nicotine but not ethanol preference by the mouse Chrna4 A529T polymorphism. Behav Neurosci 119:26–37PubMedGoogle Scholar
  39. Cam GR, Bassett JR (1984) Effect of prolonged exposure to nicotine and stress on the pituitary-adrenocortical response; the possibility of cross-adaptation. Pharmacol Biochem Behav 20:221–226PubMedGoogle Scholar
  40. Cardoso RA, Brozowski SJ, Chavez-Noriega LE, Harpold M, Valenzuela CF, Harris RA (1999) Effects of ethanol on recombinant human neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Pharmacol Exp Ther 289:774–780PubMedGoogle Scholar
  41. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C et al (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23:7820–7829PubMedGoogle Scholar
  42. Chen MF, Chiu TH, Lee EH (1992) Noradrenergic mediation of the memory-enhancing effect of corticotropin-releasing factor in the locus coeruleus of rats. Psychoneuroendocrinology 17:113–124PubMedGoogle Scholar
  43. Chen X, Chen J, Williamson VS, An SS, Hettema JM, Aggen SH et al (2009) Variants in nicotinic acetylcholine receptors alpha5 and alpha3 increase risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet 150B(7):966–1033Google Scholar
  44. Chi H, de Wit H (2003) Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. Alcohol Clin Exp Res 27:780–786PubMedGoogle Scholar
  45. Ciccocioppo R, Economidou D, Cippitelli A, Cucculelli M, Ubaldi M, Soverchia L et al (2006) Genetically selected Marchigian Sardinian alcohol-preferring (msP) rats: an animal model to study the neurobiology of alcoholism. Addict Biol 11:339–355PubMedCentralPubMedGoogle Scholar
  46. Clarke PB, Schwartz RD, Paul SM, Pert CB, Pert A (1985) Nicotinic binding in rat brain: autoradiographic comparison of [3H] acetylcholine, [3H] nicotine, and [125I]-alpha-bungarotoxin. J Neurosci 5:1307–1315PubMedGoogle Scholar
  47. Clarke PB, Fu DS, Jakubovic A, Fibiger HC (1988) Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J pharmacol exp ther 246:701–708PubMedGoogle Scholar
  48. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang J et al (2005a) Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48:3474–3477PubMedGoogle Scholar
  49. Coe JW, Vetelino MG, Bashore CG, Wirtz MC, Brooks PR, Arnold EP et al (2005b) In pursuit of alpha4 beta2 nicotinic receptor partial agonists for smoking cessation: carbon analogs of (-)-cytisine. Bioorg Med Chem Lett 15:2974–2979PubMedGoogle Scholar
  50. Colquhoun LM, Patrick JW (1997) Pharmacology of neuronal nicotinic acetylcholine receptor subtypes. Adv pharmacol (San Diego, Calif) 39:191–220Google Scholar
  51. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC et al (2010) Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27:417–425PubMedGoogle Scholar
  52. Corringer PJ, Le Novere N, Changeux JP (2000) Nicotinic receptors at the amino acid level. Annu Rev Pharmacol Toxicol 40:431–458PubMedGoogle Scholar
  53. Crabbe JC, Phillips TJ (2004) Pharmacogenetic studies of alcohol self-administration and withdrawal. Psychopharmacology 174(4):539–560PubMedGoogle Scholar
  54. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N et al (1997) Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132:107–124Google Scholar
  55. Cui C, Booker TK, Allen RS, Grady SR, Whiteaker P, Marks MJ et al (2003) The beta3 nicotinic receptor subunit: a component of alpha-conotoxin MII-binding nicotinic acetylcholine receptors that modulate dopamine release and related behaviors. J Neurosci 23:11045–11053PubMedGoogle Scholar
  56. D’Hoedt D, Bertrand D (2009) Nicotinic acetylcholine receptors: an overview on drug discovery. Expert opin ther targets 13:395–411PubMedGoogle Scholar
  57. Dani JA, Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699–729PubMedGoogle Scholar
  58. De Felipe C, Herrero JF, O’Brien JA, Palmer JA, Doyle CA, Smith AJ et al (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392:394–397PubMedGoogle Scholar
  59. Deneris ES, Connolly J, Rogers SW, Duvoisin R (1991) Pharmacological and functional diversity of neuronal nicotinic acetylcholine receptors. Trends Pharmacol Sci 12:34–40PubMedGoogle Scholar
  60. Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393:295–314PubMedGoogle Scholar
  61. Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations int he mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278PubMedGoogle Scholar
  62. Diana M, Brodie M, Muntoni A, Puddu MC, Pillolla G, Steffensen S et al (2003) Enduring effects of chronic ethanol in the CNS: basis for alcoholism. Alcohol Clin Exp Res 27:354–361PubMedGoogle Scholar
  63. DiLeone RJ, Georgescu D, Nestler EJ (2003) Lateral hypothalamic neuropeptides in reward and drug addiction. Life Sci 73:759–768PubMedGoogle Scholar
  64. Ducci F, Enoch MA, Funt S, Virkkunen M, Albaugh B, Goldman D (2007) Increased anxiety and other similarities in temperament of alcoholics with and without antisocial personality disorder across three diverse populations. Alcohol 41:3–12PubMedCentralPubMedGoogle Scholar
  65. Ebner K, Singewald N (2007) Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 376:73–82PubMedGoogle Scholar
  66. Ebner K, Rupniak NM, Saria A, Singewald N (2004) Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 101:4280–4285PubMedGoogle Scholar
  67. Ebner K, Muigg P, Singewald G, Singewald N (2008a) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci 1144:61–73PubMedGoogle Scholar
  68. Ebner K, Singewald GM, Whittle N, Ferraguti F, Singewald N (2008b) Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology 33:1929–1941PubMedGoogle Scholar
  69. Edwards G, Gross MM (1976) Alcohol dependence: provisional description of a clinical syndrome. Br Med J 1:1058–1061PubMedCentralPubMedGoogle Scholar
  70. Egli M (2005) Can experimental paradigms and animal models be used to discover clinically effective medications for alcoholism? Addict Biol 10:309–319PubMedGoogle Scholar
  71. Elliott PJ (1988) Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: implication of substance P in aversion. Exp Brain Res 73:354–356PubMedGoogle Scholar
  72. Ericson M, Blomqvist O, Engel JA, Soderpalm B (1998) Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine. Eur J Pharmacol 358:189–196PubMedGoogle Scholar
  73. Ericson M, Molander A, Lof E, Engel JA, Soderpalm B (2003) Ethanol elevates accumbal dopamine levels via indirect activation of ventral tegmental nicotinic acetylcholine receptors. Eur J Pharmacol 467:85–93PubMedGoogle Scholar
  74. Ericson M, Lof E, Stomberg R, Soderpalm B (2009) The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system. J Pharmacol Exp Ther 329(1):225–230PubMedGoogle Scholar
  75. Euler US, Gaddum JH (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72:74Google Scholar
  76. File SE (1997) Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 58:747–752PubMedGoogle Scholar
  77. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ (1992) A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol 41:31–37PubMedGoogle Scholar
  78. Funk CK, O’Dell LE, Crawford EF, Koob GF (2006a) Corticotropin-releasing factor within the central nucleus of the amygdala mediates enhanced ethanol self-administration in withdrawn, ethanol-dependent rats. J Neurosci 26:11324–11332PubMedGoogle Scholar
  79. Funk D, Li Z, Le AD (2006b) Effects of environmental and pharmacological stressors on c-fos and corticotropin-releasing factor mRNA in rat brain: relationship to the reinstatement of alcohol seeking. Neuroscience 138:235–243PubMedGoogle Scholar
  80. Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF (2007) Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biol Psychiatry 61:78–86PubMedCentralPubMedGoogle Scholar
  81. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S et al (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58:132–142PubMedGoogle Scholar
  82. Gadd CA, Murtra P, De Felipe C, Hunt SP (2003) Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23:8271–8280PubMedGoogle Scholar
  83. Gallegos RA, Lee RS, Criado JR, Henriksen SJ, Steffensen SC (1999) Adaptive responses of gamma-aminobutyric acid neurons in the ventral tegmental area to chronic ethanol. J Pharmacol Exp Ther 291:1045–1053PubMedGoogle Scholar
  84. Gehlert DR, Cippitelli A, Thorsell A, Le AD, Hipskind PA, Hamdouchi C et al (2007) 3-(4-Chloro-2-morpholin-4-yl-thiazol-5-yl)-8-(1-ethylpropyl)-2, 6-dimethyl- imidazo [1, 2-b]pyridazine: a novel brain-penetrant, orally available corticotropin-releasing factor receptor 1 antagonist with efficacy in animal models of alcoholism. J Neurosci 27:2718–2726PubMedGoogle Scholar
  85. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C et al (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319:1536–1539PubMedGoogle Scholar
  86. Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G (1985) Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 348:201–203PubMedGoogle Scholar
  87. Ghitza UE, Gray SM, Epstein DH, Rice KC, Shaham Y (2006) The anxiogenic drug yohimbine reinstates palatable food seeking in a rat relapse model: a role of CRF1 receptors. Neuropsychopharmacology 31:2188–2196PubMedCentralPubMedGoogle Scholar
  88. Gilman JM, Hommer DW (2008) Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patients. Addict Biol 13:423–434PubMedGoogle Scholar
  89. Gilman JM, Ramchandani VA, Davis MB, Bjork JM, Hommer DW (2008) Why we like to drink: a functional magnetic resonance imaging study of the rewarding and anxiolytic effects of alcohol. J Neurosci 28:4583–4591PubMedCentralPubMedGoogle Scholar
  90. Goldstein DB, Pal N (1971) Alcohol dependence produced in mice by inhalation of ethanol–grading withdrawal reaction. Science 172:288–290PubMedGoogle Scholar
  91. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB et al (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 296:47–55PubMedGoogle Scholar
  92. Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog Neurobiol 74:363–396PubMedGoogle Scholar
  93. Gotti C, Fornasari D, Clementi F (1997) Human neuronal nicotinic receptors. Prog Neurobiol 53:199–237PubMedGoogle Scholar
  94. Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27:482–491PubMedGoogle Scholar
  95. Gotti C, Clementi F, Fornari A, Gaimarri A, Guiducci S, Manfredi I et al (2009) Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem Pharmacol 78:703–711PubMedGoogle Scholar
  96. Griebel G, Simiand J, Steinberg R, Jung M, Gully D, Roger P et al (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl] 5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333–345PubMedGoogle Scholar
  97. Griffin WC, Lopez MF, Yanke AB, Middaugh LD, Becker HC (2009) Repeated cycles of chronic intermittent ethanol exposure in mice increases voluntary ethanol drinking and ethanol concentrations in the nucleus accumbens. Psychopharmacology (Berl) 201:569–580Google Scholar
  98. Grosshans M, Mutschler J, Hermann D, Mann K, Diehl A (2009) Reduced affective symptoms during tobacco dependence treatment with varenicline. Addiction 104:859–861PubMedGoogle Scholar
  99. Grucza RA, Wang JC, Stitzel JA, Hinrichs AL, Saccone SF, Saccone NL et al (2008) A risk allele for nicotine dependence in CHRNA5 is a protective allele for cocaine dependence. Biol Psychiatry 64:922–929PubMedCentralPubMedGoogle Scholar
  100. Gully D, Geslin M, Serva L, Fontaine E, Roger P, Lair C et al (2002) 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl) ethyl] 5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor (1) receptor antagonist. I. Biochemical and pharmacological characterization. J Pharmacol Exp Ther 301:322–332PubMedGoogle Scholar
  101. Gunnell D, Irvine D, Wise L, Davies C, Martin RM (2009) Varenicline and suicidal behaviour: a cohort study based on data from the general practice research database. BMJ 339:b3805PubMedCentralPubMedGoogle Scholar
  102. Hansson AC, Cippitelli A, Sommer WH, Fedeli A, Bjork K, Soverchia L et al (2006) Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci USA 103:15236–15241PubMedGoogle Scholar
  103. Hansson AC, Cippitelli A, Sommer W, Ciccocioppo R, Heilig M (2007) Region-specific down regulation of Crhr1 gene expression in alcohol preferring msP rats following ad lib access to alcohol. Addict Biol 12:30–34PubMedGoogle Scholar
  104. Harris GC, Wimmer M, Aston-Jones G (2005) A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437:556–559PubMedGoogle Scholar
  105. Hasin DS, Stinson FS, Ogburn E, Grant BF (2007) Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 64:830–842PubMedGoogle Scholar
  106. Heilig M, Egli M (2006) Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharm Therap 111:855–876Google Scholar
  107. Heilig M, Koob GF (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30:399–406PubMedCentralPubMedGoogle Scholar
  108. Hill JA Jr, Zoli M, Bourgeois JP, Changeux JP (1993) Immunocytochemical localization of a neuronal nicotinic receptor: the beta 2-subunit. J Neurosci 13:1551–1568PubMedGoogle Scholar
  109. Hokfelt T, Johansson O, Goldstein M (1984) Chemical anatomy of the brain. Science 225:1326–1334PubMedGoogle Scholar
  110. Huang YY, Kandel ER, Levine A (2008) Chronic nicotine exposure induces a long-lasting and pathway-specific facilitation of LTP in the amygdala. Learn Mem (Cold Spring Harbor, N Y) 15:603–610Google Scholar
  111. Hunt SP, Schmidt J (1978) The electron microscopic autoradiographic localization of alpha-bungarotoxin binding sites within the central nervous system of the rat. Brain Res 142:152–159PubMedGoogle Scholar
  112. Hunt WA, Barnett LW, Branch LG (1971) Relapse rates in addiction programs. J Clin Psychol 27(4):455–456PubMedGoogle Scholar
  113. Imperato A, Di Chiara G (1986) Preferential stimulation of dopamine release in the nucleus accumbens of freely moving rats by ethanol. J Pharmacol Exp Ther 239:219–228PubMedGoogle Scholar
  114. Imperato A, Mulas A, Di Chiara G (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337–338PubMedGoogle Scholar
  115. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE et al (2006) Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296:56–63PubMedGoogle Scholar
  116. Joslyn G, Brush G, Robertson M, Smith TL, Kalmijn J, Schuckit M et al (2008) Chromosome 15q25.1 genetic markers associated with level of response to alcohol in humans. Proc Natl Acad Sci USA 105:20368–20373PubMedGoogle Scholar
  117. Kalivas PW, Stewart J (1991) Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16:223–244PubMedGoogle Scholar
  118. King AC, Volpicelli JR, Frazer A, O’Brien CP (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology (Berl) 129:15–22Google Scholar
  119. Kirschbaum C, Pirke KM, Hellhammer DH (1993) The ‘trier social stress test’–a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28:76–81PubMedGoogle Scholar
  120. Klink R, de Kerchove d’Exaerde A, Zoli M, Changeux JP (2001) Molecular and physiological diversity of nicotinic acetylcholine receptors in the midbrain dopaminergic nuclei. J Neurosci 21:1452–1463PubMedGoogle Scholar
  121. Knapp DJ, Overstreet DH, Moy SS, Breese GR (2004) SB242084, flumazenil, and CRA1000 block ethanol withdrawal-induced anxiety in rats. Alcohol 32:101–111PubMedCentralPubMedGoogle Scholar
  122. Koob GF (1992) Neural mechanisms of drug reinforcement. Ann N Y Acad Sci 654:171–191PubMedGoogle Scholar
  123. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281:1640–1645PubMedGoogle Scholar
  124. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D et al (2004) Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29:385–392PubMedGoogle Scholar
  125. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O’Malley SS (2007) Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry 62:694–697PubMedGoogle Scholar
  126. Kuzmin A, Jerlhag E, Liljequist S, Engel J (2009) Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology (Berl) 203:99–108Google Scholar
  127. Lang PJ, Bradley MM, Cuthbert BN (1995) International affective picture system (IAPS): technical manual and affective ratings. The Center for Research in Psychophysiology, University of Florida: GainsvilleGoogle Scholar
  128. Larimer ME, Palmer RS, Marlatt GA (1999) Relapse prevention. An overview of Marlatt’s cognitive-behavioral model. Alcohol Res Health: J Natl Inst Alcohol Abus Alcohol 23:151–160Google Scholar
  129. Larsson A, Svensson L, Soderpalm B, Engel JA (2002) Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice. Alcohol 28:157–167PubMedGoogle Scholar
  130. Larsson A, Jerlhag E, Svensson L, Soderpalm B, Engel JA (2004) Is an alpha-conotoxin MII-sensitive mechanism involved in the neurochemical, stimulatory, and rewarding effects of ethanol? Alcohol (Fayetteville, N Y) 34:239–250Google Scholar
  131. Larsson A, Edstrom L, Svensson L, Soderpalm B, Engel JA (2005) Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. Alcohol Alcohol (Oxford, Oxfordshire) 40:349–358Google Scholar
  132. Le Novere N, Changeux JP (1995) Molecular evolution of the nicotinic acetylcholine receptor: an example of multigene family in excitable cells. J Mol Evol 40:155–172PubMedGoogle Scholar
  133. Le Novere N, Corringer PJ, Changeux JP (2002) The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol 53:447–456PubMedGoogle Scholar
  134. Le AD, Quan B, Juzytch W, Fletcher PJ, Joharchi N, Shaham Y (1998) Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. Psychopharmacology (Berl) 135:169–174Google Scholar
  135. Le AD, Poulos CX, Harding S, Watchus J, Juzytsch W, Shaham Y (1999) Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21:435–444PubMedGoogle Scholar
  136. Le AD, Corrigall WA, Harding JW, Juzytsch W, Li TK (2000a) Involvement of nicotinic receptors in alcohol self-administration. Alcohol Clin Exp Res 24:155–163PubMedGoogle Scholar
  137. Le AD, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y (2000b) The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl) 150:317–324Google Scholar
  138. Le AD, Harding S, Juzytsch W, Fletcher PJ, Shaham Y (2002) The role of corticotropin-releasing factor in the median raphe nucleus in relapse to alcohol. J Neurosci 22:7844–7849PubMedGoogle Scholar
  139. Le AD, Wang A, Harding S, Juzytsch W, Shaham Y (2003) Nicotine increases alcohol self-administration and reinstates alcohol seeking in rats. Psychopharmacology (Berl) 168:216–221Google Scholar
  140. Le AD, Harding S, Juzytsch W, Funk D, Shaham Y (2005) Role of alpha-2 adrenoceptors in stress-induced reinstatement of alcohol seeking and alcohol self-administration in rats. Psychopharmacology (Berl) 179:366–373Google Scholar
  141. Lindstrom J, Schoepfer R, Conroy WG, Whiting P (1990) Structural and functional heterogeneity of nicotinic receptors. Ciba Found Symp 152:23–42PubMedGoogle Scholar
  142. Liu X, Weiss F (2002) Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci 22:7856–7861PubMedGoogle Scholar
  143. Liu X, Weiss F (2003) Stimulus conditioned to foot-shock stress reinstates alcohol-seeking behavior in an animal model of relapse. Psychopharmacology (Berl) 168:184–191Google Scholar
  144. Lopez MF, Becker HC (2005) Effect of pattern and number of chronic ethanol exposures on subsequent voluntary ethanol intake in C57BL/6 J mice. Psychopharmacology (Berl) 181:688–696Google Scholar
  145. Lopez MF, Anderson RI, Becker HC (2008) Repeated cycles of chronic intermittent ethanol exposure increase both self-administration and the reinforcing value of ethanol in C57BL/6 J mice. Alcohol-Clin Exp Res 32:163AGoogle Scholar
  146. Luetje CW, Patrick J, Seguela P (1990) Nicotine receptors in the mammalian brain. FASEB J 4:2753–2760PubMedGoogle Scholar
  147. Makino S, Hashimoto K, Gold PW (2002) Multiple feedback mechanisms activating corticotropin-releasing hormone system in the brain during stress. Pharmacol Biochem Behav 73:147–158PubMedGoogle Scholar
  148. Mantyh PW, Hunt SP, Maggio JE (1984) Substance-P receptors–localization by light microscopic autoradiography in rat-brain using [H-3]Sp as the radioligand. Brain Res 307:147–165PubMedGoogle Scholar
  149. Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y et al (2007) The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berl) 195:345–355Google Scholar
  150. Mark TL, Kranzler HR, Song X (2003) Understanding US addiction physicians’ low rate of naltrexone prescription. Drug Alcohol Depend 71:219–228PubMedGoogle Scholar
  151. Maskos U, Molles BE, Pons S, Besson M, Guiard BP, Guilloux JP et al (2005) Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436:103–107PubMedGoogle Scholar
  152. Matta SG, Beyer HS, McAllen KM, Sharp BM (1987) Nicotine elevates rat plasma ACTH by a central mechanism. J Pharmacol Exp Ther 243:217–226PubMedGoogle Scholar
  153. Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American society of addiction medicine working group on pharmacological management of alcohol withdrawal. JAMA 278:144–151PubMedGoogle Scholar
  154. McClure JB, Swan GE, Jack L, Catz SL, Zbikowski SM, McAfee TA et al (2009) Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med 24:563–569PubMedCentralPubMedGoogle Scholar
  155. McFarland K, Davidge SB, Lapish CC, Kalivas PW (2004) Limbic and motor circuitry underlying footshock-induced reinstatement of cocaine-seeking behavior. J Neurosci 24:1551–1560PubMedGoogle Scholar
  156. McGehee DS, Role LW (1995) Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurons. Annu Rev Physiol 57:521–546PubMedGoogle Scholar
  157. McKee SA, Harrison ELR, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault JM et al (2009) Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry 66:185–190PubMedCentralPubMedGoogle Scholar
  158. McLellan AT, Lewis DC, O’Brien CP, Kleber HD (2000) Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284:1689–1695PubMedGoogle Scholar
  159. Melendez RI, Middaugh LD, Kalivas PW (2006) Development of an alcohol deprivation and escalation effect in C57BL/6 J mice. Alcohol Clin Exp Res 30:2017–2025PubMedGoogle Scholar
  160. Merlo PE, Lorang M, Yeganeh M, Rodriguez de FF, Raber J, Koob GF et al (1995) Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 15:5439–5447Google Scholar
  161. Miller GM, Bendor J, Tiefenbacher S, Yang H, Novak MA, Madras BK (2004) A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol Psychiatry 9:99–108PubMedGoogle Scholar
  162. Monti PM, Rohsenow DJ, Rubonis AV, Niaura RS, Sirota AD, Colby SM et al (1993) Alcohol cue reactivity: effects of detoxification and extended exposure. J Stud Alcohol 54:235–245PubMedGoogle Scholar
  163. Muller MB, Wurst W (2004) Getting closer to affective disorders: the role of CRH receptor systems. Trends Mol Med 10:409–415PubMedGoogle Scholar
  164. Murtra P, Sheasby AM, Hunt SP, De Felipe C (2000) Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405:180–183PubMedGoogle Scholar
  165. Nakaya Y, Kaneko T, Shigemoto R, Nakanishi S, Mizuno N (1994) Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J Comp Neurol 347:249–274PubMedGoogle Scholar
  166. Naqvi NH, Bechara A (2009) The hidden island of addiction: the insula. Trends Neurosci 32:56–67PubMedCentralPubMedGoogle Scholar
  167. Naqvi NH, Rudrauf D, Damasio H, Bechara A (2007) Damage to the insula disrupts addiction to cigarette smoking. Science 315:531–534PubMedCentralPubMedGoogle Scholar
  168. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, Miyatake M et al (2006) Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. J Neurosci 26:398–405PubMedGoogle Scholar
  169. Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P et al (2007) Chronic nicotine cell specifically upregulates functional alpha 4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci 27:8202–8218PubMedGoogle Scholar
  170. Newlin DB, Thomson JB (1990) Alcohol challenge with sons of alcoholics—a critical-review and analysis. Psychol Bull 108:383–402PubMedGoogle Scholar
  171. Nisell M, Nomikos GG, Svensson TH (1994) Infusion of nicotine in the ventral tegmental area or the nucleus accumbens of the rat differentially affects accumbal dopamine release. Pharmacol Toxicol 75:348–352PubMedGoogle Scholar
  172. O’Dell LE, Roberts AJ, Smith RT, Koob GF (2004) Enhanced alcohol self-administration after intermittent versus continuous alcohol vapor exposure. Alcohol Clin Exp Res 28:1676–1682PubMedGoogle Scholar
  173. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49:881–887PubMedGoogle Scholar
  174. O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) 160:19–29Google Scholar
  175. Ochoa EL (2009) Varenicline reduced smoking behaviour in a mentally ill person. J Psychopharmacol 23:340–341PubMedGoogle Scholar
  176. Olive MF, Koenig HN, Nannini MA, Hodge CW (2002) Elevated extracellular CRF levels in the bed nucleus of the stria terminalis during ethanol withdrawal and reduction by subsequent ethanol intake. Pharmacol Biochem Behav 72:213–220PubMedGoogle Scholar
  177. Oroszi G, Anton RF, O’Malley S, Swift R, Pettinati H, Couper D et al (2009) OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol-Clin Exp Res 33:383–393PubMedCentralPubMedGoogle Scholar
  178. Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR et al (2003) A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28:1546–1552PubMedGoogle Scholar
  179. Overstreet DH, Knapp DJ, Breese GR (2002) Accentuated decrease in social interaction in rats subjected to repeated ethanol withdrawals. Alcohol Clin Exp Res 26:1259–1268PubMedCentralPubMedGoogle Scholar
  180. Overstreet DH, Knapp DJ, Breese GR (2004) Modulation of multiple ethanol withdrawal-induced anxiety-like behavior by CRF and CRF1 receptors. Pharmacol Biochem Behav 77:405–413PubMedCentralPubMedGoogle Scholar
  181. Owens JC, Balogh SA, McClure-Begley TD, Butt CM, Labarca C, Lester HA et al (2003) Alpha 4 beta 2* nicotinic acetylcholine receptors modulate the effects of ethanol and nicotine on the acoustic startle response. Alcohol Clin Exp Res 27:1867–1875PubMedGoogle Scholar
  182. Pabreza LA, Dhawan S, Kellar KJ (1991) [3H] cytisine binding to nicotinic cholinergic receptors in brain. Mol Pharmacol 39:9–12PubMedGoogle Scholar
  183. Paneda C, Winsky-Sommerer R, Boutrel B, de Lecea L (2005) The corticotropin-releasing factor-hypocretin connection: implications in stress response and addiction. Drug News Perspect 18:250–255PubMedGoogle Scholar
  184. Papp M, Vassout A, Gentsch C (2000) The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 115:19–23PubMedGoogle Scholar
  185. Pasumarthi RK, Reznikov LR, Fadel J (2006) Activation of orexin neurons by acute nicotine. Eur J Pharmacol 535:172–176PubMedGoogle Scholar
  186. Patrick J, Sequela P, Vernino S, Amador M, Luetje C, Dani JA (1993) Functional diversity of neuronal nicotinic acetylcholine receptors. Prog Brain Res 98:113–120PubMedGoogle Scholar
  187. Payan DG (1989) Neuropeptides and inflammation: the role of substance P. Annu Rev Med 40:341–352PubMedGoogle Scholar
  188. Philip NS, Carpenter LL, Tyrka AR, Whiteley LB, Price LH (2009) Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry 70:1026–1031PubMedGoogle Scholar
  189. Picciotto MR, Zoli M, Zachariou V, Changeux JP (1997) Contribution of nicotinic acetylcholine receptors containing the beta 2-subunit to the behavioural effects of nicotine. Biochem Soc Trans 25:824–829PubMedGoogle Scholar
  190. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, Damadzic R, Eskay R, Schoor M, Thorsell A, Schwandt ML, Sommer WH, George DT, Parsons LH, Herscovitch P, Hommer D, Heilig M (2010) A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry (Epub ahead of print)Google Scholar
  191. Ramon JM, Bruguera E (2009) Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Public Health 6:1530–1538PubMedGoogle Scholar
  192. Rassnick S, Heinrichs SC, Britton KT, Koob GF (1993) Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 605:25–32PubMedGoogle Scholar
  193. Rehm J, Room R, Graham K, Monteiro M, Gmel G, Sempos CT (2003) The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 98:1209–1228PubMedGoogle Scholar
  194. Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J (2009) Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373:2223–2233PubMedGoogle Scholar
  195. Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, Bonci A et al (2008) Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. Psychopharmacology (Berl) 199:109–117Google Scholar
  196. Rimondini R, Arlinde C, Sommer W, Heilig M (2002) Long-lasting increase in voluntary ethanol consumption and transcriptional regulation in the rat brain after intermittent exposure to alcohol. FASEB J 16:27–35PubMedGoogle Scholar
  197. Rimondini R, Sommer W, Heilig M (2003) A temporal threshold for induction of persistent alcohol preference: behavioral evidence in a rat model of intermittent intoxication. J Stud Alcohol 64:445–449PubMedGoogle Scholar
  198. Ripley TL, Gadd CA, De Felipe C, Hunt SP, Stephens DN (2002) Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology 43:1258–1268PubMedGoogle Scholar
  199. Roberts AJ, Heyser CJ, Cole M, Griffin P, Koob GF (2000) Excessive ethanol drinking following a history of dependence: animal model of allostasis. Neuropsychopharmacology 22:581–594PubMedGoogle Scholar
  200. Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction (Abingdon, England) 95(Suppl 2):S91–S117Google Scholar
  201. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA et al (2007) Pharmacological profile of the alpha(4) beta(2) nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 52:985–994PubMedGoogle Scholar
  202. Rose JE, Behm FM, Westman EC, Levin ED, Stein RM, Ripka GV (1994) Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clin Pharmacol Ther 56:86–99PubMedGoogle Scholar
  203. Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T (2005) Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone? Alcohol Alcohol 40:227–233PubMedGoogle Scholar
  204. Rupniak NM, Carlson EC, Harrison T, Oates B, Seward E, Owen S et al (2000) Pharmacological blockade or genetic deletion of substance P (NK(1)) receptors attenuates neonatal vocalisation in guinea-pigs and mice. Neuropharmacology 39:1413–1421PubMedGoogle Scholar
  205. Rupniak NMJ, Carlson EJ, Webb JK, Harrison T, Porsolt RD, Roux S et al (2001) Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12:497–508PubMedGoogle Scholar
  206. Saccone NL, Saccone SF, Hinrichs AL, Stitzel JA, Duan W, Pergadia ML et al (2009) Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am J Med Genet B Neuropsychiatr Genet 150B(4):453–466PubMedCentralPubMedGoogle Scholar
  207. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R et al (2001) Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98:1912–1917PubMedGoogle Scholar
  208. Sargent PB (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 16:403–443PubMedGoogle Scholar
  209. Schuckit MA, Hesselbrock V (1994) Alcohol dependence and anxiety disorders: what is the relationship? Am J Psychiatry 151:1723–1734PubMedGoogle Scholar
  210. Schultz W (2002) Getting formal with dopamine and reward. Neuron 36:241–263PubMedGoogle Scholar
  211. Shabalina SA, Zaykin DV, Gris P, Ogurtsov AY, Gauthier J, Shibata K et al (2009) Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet 18:1037–1051PubMedGoogle Scholar
  212. Shaham Y, Shalev U, Lu L, de Wit H, Stewart J (2003) The reinstatement model of drug relapse: history, methodology and major findings. Psychopharmacology (Berl) 168:3–20Google Scholar
  213. Shepard JD, Bossert JM, Liu SY, Shaham Y (2004) The anxiogenic drug yohimbine reinstates methamphetamine seeking in a rat model of drug relapse. Biol Psychiatry 55:1082–1089PubMedGoogle Scholar
  214. Smith RJ, Aston-Jones G (2008) Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 213:43–61PubMedCentralPubMedGoogle Scholar
  215. Smith RC, Lindenmayer JP, Davis JM, Cornwell J, Noth K, Gupta S et al (2009) Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder. Schizophr Res 110:149–155PubMedGoogle Scholar
  216. Sobell MB, Sobell LC (1993) Treatment for problem drinkers: A public health priority. In: Baer JS, Marlatt GA, McMahon RJ (eds) Addictive behaviors across the lifespan: prevention, treatment, and policy issues. Sage, Beverly Hills, CA, pp 138–157Google Scholar
  217. Sommer WH, Rimondini R, Hansson AC, Hipskind PA, Gehlert DR, Barr CS et al (2008) Upregulation of voluntary alcohol intake, behavioral sensitivity to stress, and amygdala Crhr1 expression following a history of dependence. Biol Psychiatry 63:139–145PubMedGoogle Scholar
  218. Spanagel R, Herz A, Shippenberg TS (1992) Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci USA 89:2046–2050PubMedGoogle Scholar
  219. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG (2006) Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev 58:46–57PubMedGoogle Scholar
  220. Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcliffe M et al (2008) Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 103:146–154PubMedGoogle Scholar
  221. Steensland P, Simms JA, Holgate J, Richards JK, Bartlett SE (2007) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proc Natl Acad Sci USA 104:12518–12523PubMedGoogle Scholar
  222. Steensland P, Simms JA, Nielsen CK, Holgate J, Bito-Onon JJ, Bartlett SE (2010) The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. PLoS One. 5(9). pii: e12527Google Scholar
  223. Stevens VL, Bierut LJ, Talbot JT, Wang JC, Sun J, Hinrichs AL et al (2008) Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol Biomarkers Prev 17:3517–3525PubMedCentralPubMedGoogle Scholar
  224. Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O’Brien CP (1998) A comparison of the effects of the opioid antagonist’s naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 15:281–289PubMedGoogle Scholar
  225. Swanson LW, Sawchenko PE, Rivier J, Vale WW (1983) Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36:165–186PubMedGoogle Scholar
  226. Tanda GL, Di Chiara G (1998) A dopamine mu (1) opioid link in the rat ventral tegmentum shared by palatable food (Fonzies) and non-psychostimulant drugs of abuse. Eur J Neurosci 10:1179–1187PubMedGoogle Scholar
  227. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C et al (2004) Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 306:1029–1032PubMedGoogle Scholar
  228. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, De Lima TC (1996) Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311:7–14PubMedGoogle Scholar
  229. Thorsell A, Schank JR, Singley E, Hunt SP, Heilig M (2010) Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice. Psychopharmacology (Berl) 209:103–111Google Scholar
  230. Tizabi Y, Copeland RL Jr, Louis VA, Taylor RE (2002) Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens. Alcohol Clin Exp Res 26:394–399PubMedGoogle Scholar
  231. Tizabi Y, Bai L, Copeland RL Jr, Taylor RE (2007) Combined effects of systemic alcohol and nicotine on dopamine release in the nucleus accumbens shell. Alcohol Alcohol (Oxford, Oxfordshire) 42:413–416Google Scholar
  232. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296:64–71PubMedGoogle Scholar
  233. Treutlein J, Kissling C, Frank J, Wiemann S, Dong L, Depner M et al (2006) Genetic association of the human corticotropin releasing hormone receptor 1 (CRHR1) with binge drinking and alcohol intake patterns in two independent samples. Mol Psychiatry 11:594–602PubMedGoogle Scholar
  234. Tritto T, Marley RJ, Bastidas D, Stitzel JA, Collins AC (2001) Potential regulation of nicotine and ethanol actions by alpha4-containing nicotinic receptors. Alcohol 24:69–78PubMedGoogle Scholar
  235. Valdez GR, Roberts AJ, Chan K, Davis H, Brennan M, Zorrilla EP et al (2002) Increased ethanol self-administration and anxiety-like behavior during acute ethanol withdrawal and protracted abstinence: regulation by corticotropin-releasing factor. Alcohol Clin Exp Res 26:1494–1501PubMedGoogle Scholar
  236. Valdez GR, Zorrilla EP, Roberts AJ, Koob GF (2003) Antagonism of corticotropin-releasing factor attenuates the enhanced responsiveness to stress observed during protracted ethanol abstinence. Alcohol 29:55–60PubMedGoogle Scholar
  237. Valdez GR, Sabino V, Koob GF (2004) Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res 28:865–872PubMedGoogle Scholar
  238. Vale W, Spiess J, Rivier C, Rivier J (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213:1394–1397PubMedGoogle Scholar
  239. Vanderschuren LJ, Kalivas PW (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 151:99–120Google Scholar
  240. Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE et al (2002) The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27:371–379PubMedGoogle Scholar
  241. Vazquez-Palacios G, Bonilla-Jaime H (2004) Nicotine acetylcholine receptors and neuropsychiatric disorders. Rev Neurol 39:1146–1160PubMedGoogle Scholar
  242. Vengeliene V, Siegmund S, Singer MV, Sinclair JD, Li TK, Spanagel R (2003) A comparative study on alcohol-preferring rat lines: effects of deprivation and stress phases on voluntary alcohol intake. Alcohol Clin Exp Res 27:1048–1054PubMedGoogle Scholar
  243. Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876–880PubMedGoogle Scholar
  244. Wang JC, Grucza R, Cruchaga C, Hinrichs AL, Bertelsen S, Budde JP et al (2009) Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry 14:501–510PubMedGoogle Scholar
  245. Wise RA, Rompre PP (1989) Brain dopamine and reward. Annu Rev Psychol 40:191–225PubMedGoogle Scholar
  246. Wolf ME (1998) The role of excitatory amino acids in behavioral sensitization to psychomotor stimulants. Prog Neurobiol 54:679–720PubMedGoogle Scholar
  247. Yim HJ, Schallert T, Randall PK, Gonzales RA (1998) Comparison of local and systemic ethanol effects on extracellular dopamine concentration in rat nucleus accumbens by microdialysis. Alcohol Clin Exp Res 22:367–374PubMedGoogle Scholar
  248. Yoshida K, Engel J, Liljequist S (1982) The effect of chronic ethanol administration of high affinity 3H-nicotinic binding in rat brain. Naunyn Schmiedebergs Arch Pharmacol 321:74–76PubMedGoogle Scholar
  249. Young EM, Mahler S, Chi H, de Wit H (2005) Mecamylamine and ethanol preference in healthy volunteers. Alcohol Clin Exp Res 29:58–65PubMedGoogle Scholar
  250. Zhang HP, Luo XG, Kranzler HR, Lappalainen J, Yang BZ, Krupitsky E et al (2006) Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet 15:807–819PubMedCentralPubMedGoogle Scholar
  251. Zhao R, Chen H, Sharp BM (2007) Nicotine-induced norepinephrine release in hypothalamic paraventricular nucleus and amygdala is mediated by N-methyl-D-aspartate receptors and nitric oxide in the nucleus tractus solitarius. J Pharmacol Exp Ther 320:837–844PubMedGoogle Scholar
  252. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag A, Ising M et al (2000) Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 34:171–181PubMedGoogle Scholar
  253. Zoli M, Lena C, Picciotto MR, Changeux JP (1998) Identification of four classes of brain nicotinic receptors using beta2 mutant mice. J Neurosci 18:4461–4472PubMedGoogle Scholar
  254. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C (2002) Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum. J Neurosci 22:8785–8789PubMedGoogle Scholar
  255. Zorrilla EP, Valdez GR, Weiss F (2001) Changes in levels of regional CRF-like-immunoreactivity and plasma corticosterone during protracted drug withdrawal in dependent rats. Psychopharmacology (Berl) 158:374–381Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Preclinical Development Group, Ernest Gallo Clinic and Research CenterUniversity of California San FranciscoEmeryvilleUSA
  2. 2.National Institute on Alcohol Abuse and AlcoholismNational Institutes of HealthBethesdaUSA

Personalised recommendations